PRT062607 (Hydrochloride)

CAT:
804-HY-15323-01
Size:
5 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
PRT062607 (Hydrochloride) - image 1

PRT062607 (Hydrochloride)

  • UNSPSC Description:

    PRT062607 (P505-15) Hydrochloride is an orally available Syk inhibitor (IC50: 1 nM) that inhibits inflammation and induction Apoptosis. PRT062607 Hydrochloride exerts potent antitumor activity in tumor xenograft mouse models[1][2].
  • Target Antigen:

    Apoptosis; FAK; Mixed Lineage Kinase; PAK; Pyk2; Src; Syk
  • Type:

    Reference compound
  • Related Pathways:

    Apoptosis;Cell Cycle/DNA Damage;Cytoskeleton;MAPK/ERK Pathway;Protein Tyrosine Kinase/RTK
  • Applications:

    Cancer-Kinase/protease
  • Field of Research:

    cancer
  • Assay Protocol:

    https://www.medchemexpress.com/PRT062607-Hydrochloride.html
  • Solubility:

    10 mM in DMSO|DMSO : ≥ 33 mg/mL|H2O : ≥ 50 mg/mL
  • Smiles:

    NC(C1=CN=C(N[C@H]2[C@@H](N)CCCC2)N=C1NC3=CC=CC(N4N=CC=N4)=C3)=O.[H]Cl
  • Molecular Weight:

    429.91
  • References & Citations:

    [1]Spurgeon SE, et al. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. J Pharmacol Exp Ther. 2013 Feb;344(2):378-87.|[2]Coffey G, et al. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis. J Pharmacol Exp Ther. 2012 Feb;340(2):350-9.Harvard Medical School LINCS LIBRARY|Int J Ophthalmol. 2022 Jul 18;15(7):1044-1052.|Proc Natl Acad Sci U S A. 2022 Oct 25;119(43):e2207280119.
  • Shipping Conditions:

    Room Temperature
  • Clinical Information:

    Phase 2
  • CAS Number:

    1370261-97-4